LNZ101 (Aceclidine /Brimonidine) ophthalmic solution for presbyopia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Feb 2024: Trial registered, NCT06270030
  2. 4 Mar 2024: Trial started, NCT06270030

The trials

NCT06270030: Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia

State
Completed
Phase
Phase 1
People
21 taking part
Started
4 Mar 2024
Primary completion
10 Apr 2024
Arms
LNZ101 (Aceclidine /Brimonidine) ophthalmic solution
Results
None posted
  1. 21 Feb 2024: Trial registered
  2. 4 Mar 2024: Trial started
  3. 10 Apr 2024: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.